Danazol
Based on 4 publication(s) in Google Scholar
Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC50 of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.66%
- No. CAS: 17230-88-5
- Fòrmula: C22H27NO2
- Peso molecular:337.46
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Oxygen Sensing Compound Library
HY-L045
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Anti-Aging Natural Product Library
HY-L134
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Alkyne Compound Library
HY-L258
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Metabolism/Protease Compound Library
HY-L012
-
TGF-beta/Smad Compound Library
HY-L018
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Danazol
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Actividad biológica
Danazol (0-100 μM, 18-72 h) inhibits the proliferation and the formation of capillary-like tubular structures in HUVECs[2].
Danazol (5-20 μM, 48 h) inhibits melanogenesis in B16 cell with an IC50 of 9.3 μM by post-transcriptionally inhibiting the expression of tyrosinase protein[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 17230-88-5
-
Appearance Solid
-
Peso molecular 337.46
-
Fòrmula C22H27NO2
-
Color White to off-white
-
SMILES
C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC5=C(C=NO5)C[C@]4(C)[C@@]3([H])CC[C@@]21C
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Cardiovasc Drugs Ther
Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant. [Abstract]2022 Feb;36(1):121-129. PMID: 33411110 -
Heliyon
Zhibai dihuang pill (ZBDH) exhibits therapeutic effects on idiopathic central sexual precocity in rats by modulating the gut microflora. [Abstract]2024 Apr 16;10(9):e29723. PMID: 38707434
Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]
The rats were injected with Danazol on PND5 to induce the ICPP rat model of ICPP. The ICPP rats in the positive control group were further treated with ZBDH and GnRHa, respectively.
Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]
As shown by the results, the vaginal opening of Danazol-induced ICPP rats occurred on the PND17, which was significantly earlier than that of normal control rats; however, ZBDH and GnRHa treatments could effectively delay the vaginal opening time of ICPP rats.
Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]
The Danazol-induced idiopathic central precocious puberty (ICPP) rat model was successfully constructed and ZBDH increased the vaginal opening time. The normal estrus cycle was displayed.
Danazol purchased from MedChemExpress. Usage Cited in: Heliyon. 2024 Apr 16;10(9):e29723. [Abstract]
The results revealed that ZBDH and GnRHa could inhibit the increase of serum hormones in Danazol-induced ICPP rats.
-
Res Sq
Sex differences in viral entry protein expression, host responses to SARS-CoV-2, and in vitro responses to sex steroid hormone treatment in COVID-19. [Abstract]2020 Dec 31:rs.3.rs-100914. PMID: 33173861
Solvente y solubilidad
DMSO : 25 mg/mL (74.08 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 20 mg/mL (59.27 mM; Need ultrasonic)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.41 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2 mg/mL (5.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2 mg/mL (5.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Thomas GW, et al., Effects of danazol on endothelial cell function and angiogenesis. Fertil Steril. 2007 Oct;88(4 Suppl):1065-70. [Content Brief]
[2]. Chang TS, Lin JJ. Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells. Arch Pharm Res. 2010 Dec;33(12):1959-65. [Content Brief]
[3]. Deka SJ, et al., Danazol has potential to cause PKC translocation, cell cycle dysregulation, and apoptosis in breast cancer cells. Chem Biol Drug Des. 2017 Jun;89(6):953-963. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.9633 mL | 14.8166 mL | 29.6331 mL | 74.0829 mL |
| 5 mM | 0.5927 mL | 2.9633 mL | 5.9266 mL | 14.8166 mL | |
| 10 mM | 0.2963 mL | 1.4817 mL | 2.9633 mL | 7.4083 mL | |
| 15 mM | 0.1976 mL | 0.9878 mL | 1.9755 mL | 4.9389 mL | |
| 20 mM | 0.1482 mL | 0.7408 mL | 1.4817 mL | 3.7041 mL | |
| 25 mM | 0.1185 mL | 0.5927 mL | 1.1853 mL | 2.9633 mL | |
| 30 mM | 0.0988 mL | 0.4939 mL | 0.9878 mL | 2.4694 mL | |
| 40 mM | 0.0741 mL | 0.3704 mL | 0.7408 mL | 1.8521 mL | |
| 50 mM | 0.0593 mL | 0.2963 mL | 0.5927 mL | 1.4817 mL | |
| DMSO | 60 mM | 0.0494 mL | 0.2469 mL | 0.4939 mL | 1.2347 mL |
Danazol Related Classifications
HY-B1029 Related Classifications
Powered by Bioz